Tradestie Institutional Equity Comparison Engine
SYRE vs MANE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SYRE Overall Edge
SYRE Captures Institutional Edge (3โ0 Pillars ยท 8โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spyre Therapeutics, Inc. Common Stock (SYRE) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SYRE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MANE at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against MANE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SYRE N/M vs MANE N/M Fwd P/E
Growth & Margin Winner
SYRE
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner
SYRE
1Y +339.1% vs +239.2% ยท 52W Pos 87% vs 77%
Options & Structure Winner
SYRE
UNCLASSIFIED (10th %ile IV) vs UNCLASSIFIED (N/A IV)
SYRE
NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.37
-4.45% 1D
Market Cap
$9.9B
1M Return
+24.37%
1Y Return
+339.11%
Forward P/E
N/M
Unified AI Score
44.4 / 100
HOLD
Tech 31.0
Fund 33.0
Flow 50.0
Mom 50.0
MANE
US Equity
MANE
Institutional Equity
$128.05
-1.24% 1D
Market Cap
N/A
1M Return
+17.67%
1Y Return
+239.21%
Forward P/E
N/M
Unified AI Score
38.1 / 100
SELL
Tech 15.0
Fund 36.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SYRE +339.11%
MANE +239.21%
Spread: +29.36 pp (MANE Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
SYRE TTM Op. Margin: 0.0%
MANE TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs MANE. Trailing 12-month operating profitability (SYRE 0.0% vs MANE N/A) and valuation multiples (SYRE N/M vs MANE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SYRE | MANE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $9.9B | N/A | Larger Scale | SYRE |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | N/A | Higher Growth | SYRE |
| Operating Margin (TTM) Profitability | 0.0% | N/A | Higher Margin | SYRE |
| Net Profit Margin Profitability | 0.0% | N/A | Higher Margin | SYRE |
| Return on Equity (ROE) Capital Efficiency | -35.0% | N/A | Higher ROE | SYRE |
| 52-Week Range Position Momentum | 87% ($22โ$111) | 77% ($32โ$157) | Stronger Trend | SYRE |
| Beta / 30D Volatility Risk Regime | 1.74ฮฒ ยท 59% Vol | 1.28ฮฒ ยท 80% Vol | Lower Realized Risk | SYRE |
| Unified Institutional Score Composite Signal | 44.4 / 100 (HOLD) | 38.1 / 100 (SELL) | Higher Composite | SYRE |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SYRE vs MANE Buy Guide
SYRE
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
10th %ile
IV Regime
Compressed (<25th %ile)
MANE
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SYRE nor MANE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.